moneyheap
VRDN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Viridian Therapeutics, Inc. Common Stock (VRDN) stock moving?
VRDN closed at $30.86 on Nov 10, up about 35% from $22.82 on Oct 22. The main driver was the Q3 report on Nov 4, which showed $24.7M in Lumvoa net product revenue, more than 100 patients on therapy, and $955.2M in cash. The stock gapped up from $25.15 to $29.06 that day on 11.2M shares, roughly three times the recent average. Positive VRDN-008 Phase 1 data on Nov 9 followed: 74% peak IgG reduction, a 15-18 day half-life, and dosing every 8 weeks. The stock rose 6% to $30.19 that day, then reached $30.86 on Nov 10 on steady volume. Analysts raised targets after both events, with Leerink at $54, Wedbush at $44, Wells Fargo at $39, Truist at $42, and RBC at $41, and every update keeps a positive rating. The risks are that the VRDN-008 data are from healthy volunteers, the pivotal start is not until mid-2027 pending regulatory feedback, and the elegrobart BLA is not due until Q1 2027. The stock has also risen sharply and may be vulnerable to profit-taking.
News behind the analysis
- Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $44Wedbush kept its Outperform rating and raised its price target to $44 from $42 after the VRDN-008 Phase 1 data.
- Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $39Wells Fargo kept its Overweight rating and raised its price target to $39, up from $34 on Nov 5.
- Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week DosingViridian reported positive Phase 1 data for VRDN-008, showing prolonged IgG suppression with dosing every 8 weeks in myasthenia gravis.
- Viridian Therapeutics Announces Positive Phase 1 Results for VRDN-008VRDN-008, a half-life extended FcRn inhibitor, showed deep and sustained IgG reduction through 8 weeks after subcutaneous dosing in healthy volunteers. The company plans at least one pivotal trial in 2027, starting with myasthenia gravis in mid-2027.
- Viridian Therapeutics Announced Phase 1 Results For VRDN-008; Demonstrated Deep And Sustained IGG Reduction Through 8 Weeks After Subcutaneous Dosing, With 74% Reduction At PeakThe Phase 1 data showed a 74% peak IgG reduction and an extended half-life of 15 to 18 days, up to 6x longer than first-generation Fc fragments.
- Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54Leerink Partners kept its Outperform rating and set a $54 price target, the highest among the analyst updates in the feed.
- RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41RBC Capital kept its Outperform rating and raised its price target to $41 from $38 after the Q3 report.
- Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $42Truist reaffirmed its Buy rating and raised its price target to $42 after the Q3 report.
- Viridian Therapeutics To Present VRDN-008 Phase 1 Data And Outline FcRn Portfolio Development Plans On Monday, November 9, 2026, At 8:00 a.m. ETViridian scheduled a conference call and webcast for Nov 9 to present the VRDN-008 Phase 1 data and its FcRn portfolio plans.
About Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics is a biotech company in Waltham, Massachusetts that develops antibody medicines for thyroid eye disease (TED), an autoimmune condition, and for other autoimmune and rare diseases. Its main TED drug, veligrotug (the earlier search results also call it VRDN-001), went on sale as Lumvoa in 2026. It is also developing elegrobart, a version you inject under the skin, and a group of drugs called FcRn inhibitors.
How it makes money
Viridian has only recently started selling a product, so its revenue is still building. The main source is US sales of Lumvoa, which treats TED by blocking a target called IGF-1R and is given by IV infusion. Before that, it earned money from licensing and partnership deals; reported revenue was about $70M in 2024. The company plans to apply for approval of elegrobart, given as an injection under the skin, in early 2027. Its FcRn drugs, VRDN-006 and VRDN-008, are in early testing for a range of autoimmune diseases. Spending on research and on launching its drugs is still large, and the company has said it expects its current plans to be funded until it becomes profitable.
What usually moves VRDN
- How fast Lumvoa sales grow
- Elegrobart approval application and FDA decisions
- Trial results for its FcRn drugs VRDN-006 and VRDN-008
- Competition in thyroid eye disease from Amgen's Tepezza
- Cash on hand and any new share sales to raise money